Cargando…
Reduced plasma level of diazepam-binding inhibitor (DBI) in patients with morbid obesity
Autores principales: | Siejka, Agnieszka, Jankiewicz-Wika, Joanna, Stępień, Henryk, Fryczak, Jolanta, Świętosławski, Jacek, Komorowski, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512568/ https://www.ncbi.nlm.nih.gov/pubmed/25561371 http://dx.doi.org/10.1007/s12020-014-0522-5 |
Ejemplares similares
-
Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI)
por: Joseph, Adrien, et al.
Publicado: (2020) -
Effects of acyl-coenzyme A binding protein (ACBP)/diazepam-binding inhibitor (DBI) on body mass index
por: Joseph, Adrien, et al.
Publicado: (2021) -
Phenotypic subgrouping and multi-omics analyses reveal reduced diazepam-binding inhibitor (DBI) protein levels in autism spectrum disorder with severe language impairment
por: Pichitpunpong, Chatravee, et al.
Publicado: (2019) -
Elevated plasma levels of the appetite-stimulator ACBP/DBI in fasting and obese subjects
por: Li, Sijing, et al.
Publicado: (2021) -
Programming the Perl DBI
por: Descartes, Alligator, et al.
Publicado: (2000)